Bryan Stuart
Chief Executive Officer chez Atavistik Bio, Inc.
Fortune : 18 380 $ au 31/03/2024
Profil
Bryan E Stuart is currently the Chief Executive Officer & Director at Atavistik Bio, Inc. He previously served as the President & Chief Executive Officer at Kastle Therapeutics LLC, Yarra Therapeutics LLC, and Fulcrum Therapeutics, Inc. He was also the Chief Corporate Development Officer at EKR Therapeutics, Inc. and the VP-Corporate Development, Merger & Acquisitions at OVATION Pharmaceuticals, Inc. Additionally, he served as the Chief Business Officer at Civitas Therapeutics, Inc. Mr. Stuart received his undergraduate degree from the University of Illinois and his MBA from Kellogg School of Management.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 31/03/2023 | 1 947 ( 0,00% ) | 18 380 $ | 31/03/2024 |
Postes actifs de Bryan Stuart
| Sociétés | Poste | Début |
|---|---|---|
Atavistik Bio, Inc.
 Atavistik Bio, Inc. BiotechnologyHealth Technology Atavistik Bio, Inc. is a pre-clinical stage biotechnology company located in an undisclosed location. The American company is pioneering a synthetic, scalable approach to identify and harness highly conserved protein-metabolite interactions to revolutionize small molecule drug discovery. The company's advanced data analytics and AI platforms leverage structure-based drug design to engineer novel, highly specific small molecule drugs to activate, inhibit or stabilize targets. The company is led by an experienced management team and advisors, plus a robust investment syndicate, and is positioned to deliver transformational science to ultimately improve patient care. Atavistik Bio was founded by prominent scientists who are considered among the leading authorities in cell biology, cancer cell biology and cell metabolism. Bryan E Stuart has been the CEO of the company since 2023. | Chief Executive Officer | 17/07/2023 |
Anciens postes connus de Bryan Stuart
| Sociétés | Poste | Fin |
|---|---|---|
| FULCRUM THERAPEUTICS, INC. | Chief Executive Officer | 02/01/2023 |
| Yarra Therapeutics LLC | Chief Executive Officer | 01/08/2018 |
Kastle Therapeutics LLC
 Kastle Therapeutics LLC Medical/Nursing ServicesHealth Services Kastle Therapeutics LLC develops therapeutics targeted towards patients with high unmet medical needs. The company is headquartered in Chicago, IL. | Chief Executive Officer | 01/11/2017 |
Civitas Therapeutics, Inc.
 Civitas Therapeutics, Inc. BiotechnologyHealth Technology Civitas Therapeutics, Inc. develops transformative pulmonary delivery therapies. The company was founded by Glenn Batchelder, Richard P. Batycky, Martin I. Freed, Jennifer Fujii, Jeffrey Elton and James L. Wright on June 17, 2009 and is headquartered in Ardsley, NY. | Corporate Officer/Principal | 01/10/2014 |
EKR Therapeutics, Inc.
 EKR Therapeutics, Inc. Hospital/Nursing ManagementHealth Services EKR Therapeutics, Inc. is a specialty pharmaceutical company focused on acquiring, developing and maximizing the potential utility of critical-care hospital products offering broader therapeutic options and greater control to improve in-patient care, speed recovery, and achieve optimal outcomes. Backed by the strength of its award winning management team, the dedication of its field force of product specialists and its commitment to excellence in customer service and medical education, EKR has been organized to be a class leader in commercializing products to address unmet and under-satisfied medical needs or to otherwise enhance the therapeutic value of acute-care products. | Corporate Officer/Principal | 01/06/2012 |
Formation de Bryan Stuart
| University of Illinois | Undergraduate Degree |
| Kellogg School of Management | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| FULCRUM THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 6 |
|---|---|
EKR Therapeutics, Inc.
EKR Therapeutics, Inc. Hospital/Nursing ManagementHealth Services EKR Therapeutics, Inc. is a specialty pharmaceutical company focused on acquiring, developing and maximizing the potential utility of critical-care hospital products offering broader therapeutic options and greater control to improve in-patient care, speed recovery, and achieve optimal outcomes. Backed by the strength of its award winning management team, the dedication of its field force of product specialists and its commitment to excellence in customer service and medical education, EKR has been organized to be a class leader in commercializing products to address unmet and under-satisfied medical needs or to otherwise enhance the therapeutic value of acute-care products. | Health Services |
OVATION Pharmaceuticals, Inc.
 OVATION Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OVATION Pharmaceuticals, Inc. develops, manufactures and markets pharmaceuticals. It focuses on central nervous system, hematology or oncology and hospital-based therapies. The company was founded by Jeffrey S. Aronin in 2000 and is headquartered in Deerfield, IL. | Health Technology |
Civitas Therapeutics, Inc.
Civitas Therapeutics, Inc. BiotechnologyHealth Technology Civitas Therapeutics, Inc. develops transformative pulmonary delivery therapies. The company was founded by Glenn Batchelder, Richard P. Batycky, Martin I. Freed, Jennifer Fujii, Jeffrey Elton and James L. Wright on June 17, 2009 and is headquartered in Ardsley, NY. | Health Technology |
Kastle Therapeutics LLC
Kastle Therapeutics LLC Medical/Nursing ServicesHealth Services Kastle Therapeutics LLC develops therapeutics targeted towards patients with high unmet medical needs. The company is headquartered in Chicago, IL. | Health Services |
| Yarra Therapeutics LLC | |
Atavistik Bio, Inc.
Atavistik Bio, Inc. BiotechnologyHealth Technology Atavistik Bio, Inc. is a pre-clinical stage biotechnology company located in an undisclosed location. The American company is pioneering a synthetic, scalable approach to identify and harness highly conserved protein-metabolite interactions to revolutionize small molecule drug discovery. The company's advanced data analytics and AI platforms leverage structure-based drug design to engineer novel, highly specific small molecule drugs to activate, inhibit or stabilize targets. The company is led by an experienced management team and advisors, plus a robust investment syndicate, and is positioned to deliver transformational science to ultimately improve patient care. Atavistik Bio was founded by prominent scientists who are considered among the leading authorities in cell biology, cancer cell biology and cell metabolism. Bryan E Stuart has been the CEO of the company since 2023. | Health Technology |
